Merck, Schering-Plough, Eli Lilly see second quarter losses

Share this article:

Merck, Schering-Plough and Eli Lilly all posted second quarter losses this week.
Merck's second quarter profit fell 59 percent, hurt by the withdrawal of its blockbuster pain reliever Vioxx. Total worldwide sales were $5.5 billion for the quarter, down from $6 billion for the second quarter of 2004.
Schering-Plough posted a loss of $70 million compared with a loss of $65 million a year earlier. Schering-Plough's inflammatory disorder treatment Remicade saw sales rise 29 percent and brain tumor treatment Temodar saw a sales increase of 42 percent. The company is currently under investigation by the U.S. Attorney's Office for the District of Massachusetts for its marketing, sales and pricing practices and is also up against an investigation and lawsuits regarding wholesale prices in certain states.
Eli Lilly saw second quarter losses related to a liability settlement involving its top-selling antipsychotic Zyprexa. Lilly posted a second quarter loss of $252 million compared with a profit of $656 million a year earlier. Sales of Lilly's osteoporosis treatment Forteo rose 56 percent to $101 million and chemotherapy Gezmar jumped 17 percent to $343 million from the same quarter one year ago. Zyprexa sales fell 10 percent to $1.1 billion from $1.2 billion a year earlier and attention deficit disorder treatment Strattera fell 31 percent to $123 million after recently receiving a warning about side effects.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.